112830-95-2 Usage
Description
HU-210 (exempt preparation) (Item No. 90083) is an analytical reference standard categorized as a synthetic cannabinoid. HU-210 is regulated as a Schedule I compound in the United States. HU-210 (exempt preparation) (Item No. 90083) is provided as a DEA exempt preparation. This product is intended for research and forensic applications.
Chemical Properties
liquid
Uses
A synthetic agonist analog of ?9-Tetrahydro Cannabinol (T293200), which is the primary psychoactive component of marijuana. HU-210 is a potent central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptor agonist. It binds to neuroblastoma cell membrane CB1 receptors with about the same affinity as CP-55940.
Controlled Substance.
Biological Activity
A highly potent cannabinoid receptor agonist (K i values are 0.061 and 0.52 nM at cloned human CB 1 and CB 2 receptors respectively). Induces spatial memory deficits and suppresses hippocampal firing rates in rats. Also displays agonist activity at GPR55 (EC 50 = 26 nM). Also available as part of the Cannabinoid Receptor Agonist Tocriset? .
Check Digit Verification of cas no
The CAS Registry Mumber 112830-95-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,8,3 and 0 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 112830-95:
(8*1)+(7*1)+(6*2)+(5*8)+(4*3)+(3*0)+(2*9)+(1*5)=102
102 % 10 = 2
So 112830-95-2 is a valid CAS Registry Number.
InChI:InChI=1/C25H38O3/c1-6-7-8-9-12-24(2,3)18-14-21(27)23-19-13-17(16-26)10-11-20(19)25(4,5)28-22(23)15-18/h13-15,19-20,26-27H,6-12,16H2,1-5H3/t19-,20-/m0/s1
112830-95-2Relevant articles and documents
SYNTHESIS OF THE INDIVIDUAL, PHARMACOLOGICALLY DISTINCT, ENANTIOMERS OF A TETRAHYDROCANNABINOL DERIVATIVE
Mechoulam, Raphael,Lander, Naftali,Breuer, Aviva,Zahalka, Jamal
, p. 315 - 318 (2007/10/02)
The individual enantiomers of the 1,1-dimethylheptyl homolog of 7-hydroxy-Δ6-tetrahydrocannabinol, (1) and (2a), which exhibit distinct pharmacological profiles, have been obtained with very high e.e. by synthesis from the antipodes of myrtenol.